#BTKinhibitor hashtag - Bluesky

40:40 Recruitment - celia@4040recruitment.co.uk

@4040rec.bsky.social

1 month ago

Novartis CEO projects 2026 growth despite ‘largest patent expiry’ in company history Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter

#Novartis #VasNarasimhan #patentexpirations #patentcliff #Entresto #Pluvicto #Kisqali #BTKinhibitors #PSMAtargetedradioligandtherapy #prostatecancer #BTKinhibitor #chronicspontaneousurticaria #multiplesclerosis #Rhapsido #relapsingMS #MS #antibodies #Bcellpathways #Kesimpta
zurl.co/n0N8z

0 0 0 0

pharmaphorum

@pharmaphorum.bsky.social

3 months ago

#Shares in #Sanofi were sliding today after a double dose of bad news for its oral #BTKinhibitor tolebrutinib, in development as a therapy for #multiplesclerosis (MS).

buff.ly/zKhsMA8

0 0 0 0

Rare Disease Advisor

@rarediseaseadvisor.bsky.social

3 months ago

Pirtobrutinib Approved for R/R CLL/SLL After Covalent BTK Therapy The FDA expanded approval of pirtobrutinib (Jaypirca) to adults with R/R CLL or SLL previously treated with a covalent BTK inhibitor.

#Pirtobrutinib (#Jaypirca®), a first-in-class noncovalent #BTKInhibitor, has been approved by the @fda.gov for adults with relapsed or refractory #CLL or #SLL who were previously treated with a covalent #BTKInhibitor, @elilillyandcompany.bsky.social announced.

Read more: https://bit.ly/3YoeE7K

0 0 0 0

@d-and-d-world.bsky.social

3 months ago

Sanofi’s ASH 2025: Redefining rare blood disorder care Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company's dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.

Sanofi’s #ASH25 data highlight leadership in rare blood diseases, from multi-immune modulation with #BTKinhibitor Wayrilz to long-term hemophilia care with ALTUVIIIO. Transforming patient lives through science.
#News #Interview #RareDisease #Hemophilia #Immunoscience

1 0 0 0

Phalguni Deswal

@phalguniddw.bsky.social

3 months ago

Sanofi’s ASH 2025: Redefining rare blood disorder care Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company's dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.

Sanofi’s #ASH25 data highlight leadership in rare blood diseases, from multi-immune modulation with #BTKinhibitor Wayrilz to long-term hemophilia care with ALTUVIIIO. Transforming patient lives through science.
#News #Interview #RareDisease #Hemophilia #Immunoscience

1 0 0 0

星良孝 Yoshitaka Hoshi

@yoshitakahoshi.bsky.social

4 months ago

Merck、ASH 2025で血液がん新薬MK-1045・bomedemstat・nemtabrutinibなど20超の新データを発表 | STELLANEWS.LIFE MerckはASH 2025にて、CD19xCD3 T細胞エンゲージャーMK-1045、LSD1阻害剤bomedemstat、BTK阻害剤nemtabrutinibなど、血液がん領域における複数のモダリティの新データを発表予定。20本以上のアブストラクトで技術進展を示す。

Merck to Present Over 20 New Hematology Data Sets at ASH 2025, Highlighting Next-Generation Oncology Pipeline

🔗 Full article: stellanews.life/technology_c...

#Merck #MSD #ASH2025 #Hematology #Oncology #ClinicalResearch #BTKinhibitor #ADC #TCellEngager #Bomedemstat #Nemtabrutinib #Biopharma

0 0 0 0

@seldon-dengyue.bsky.social

4 months ago

📢 Breaking News!
The NMPA has conditionally approved #Lisaftoclax Tablets 💊—an innovative drug by Suzhou Ascentage Pharma Company Limited.

📎 Learn more: dengyuemed.com/product/asce...

📧 info@dengyuemed.com
#AscentagePharma #NMPAApproval #CLL #SLL #BTKInhibitor
#HongKongDengYueMedicine

0 0 0 0

pharmaphorum

@pharmaphorum.bsky.social

6 months ago

FDA clears Novartis' oral drug for chronic hives Novartis has claimed a first-in-class approval in the US for its oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria.

#Novartis has claimed a first-in-class #regulatoryapproval in the US for oral #BTKinhibitor remibrutinib as a second-line treatment for #chronicspontaneousurticaria (CSU), also known as chronic #hives.

0 0 0 0

@d-and-d-world.bsky.social

7 months ago

FDA clears Sanofi’s Wayrilz as first for rare blood disorder The US regulatory agency approves Sanofi’s Wayrilz as the first BTK inhibitor for treating persistent or chronic immune thrombocytopenia.

🚨 FDA approval alert: Sanofi’s Wayrilz (rilzabrutinib) becomes the first BTK inhibitor for adults with chronic immune thrombocytopenia (ITP). Backed by strong Phase 3 data, this marks a new era in rare blood disorder care.

#News #Wayrilz #FDAApproval #ITP #RareDisease #Hematology #BTKinhibitor

0 0 0 0

Phalguni Deswal

@phalguniddw.bsky.social

7 months ago

FDA clears Sanofi’s Wayrilz as first for rare blood disorder The US regulatory agency approves Sanofi’s Wayrilz as the first BTK inhibitor for treating persistent or chronic immune thrombocytopenia.

🚨 FDA approval alert: Sanofi’s Wayrilz (rilzabrutinib) becomes the first BTK inhibitor for adults with chronic immune thrombocytopenia (ITP). Backed by strong Phase 3 data, this marks a new era in rare blood disorder care.

#News #Wayrilz #FDAApproval #ITP #RareDisease #Hematology #BTKinhibitor

0 0 0 0

pharmaphorum

@pharmaphorum.bsky.social

7 months ago

Sanofi breaks new ground for BTK drugs with ITP approval Sanofi's BTK inhibitor Wayrilz has become the first drug in the class to be approved for rare platelet-busting disease immune thrombocytopenia.

#Sanofi's #BTKinhibitor Wayrilz has become the first drug in the class to be approved by the FDA for immune #thrombocytopenia (ITP), a rare #autoimmune blood disorder.

pharmaphorum.com/news/sanofi-...

0 0 0 0